NCT01689233已完成3 期
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of TRx0237 in Subjects With Mild Alzheimer's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 800
- 试验地点
- 95
- 主要终点
- Change from Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)
研究概览
简要总结
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild Alzheimer's Disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- — 至 89 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of all cause dementia and probable Alzheimer's disease
- •Clinical Dementia Rating (CDR) total score of 0.5 or 1 (mild) and MMSE score of 20-26 (inclusive)
- •Age <90 years
- •Modified Hachinski ischemic score of ≤4
- •Females, if of child-bearing potential, must practice true abstinence or be competent to use adequate contraception and agree to maintain this throughout the study
- •Subject, and/or, in the case of reduced decision-making capacity, legally acceptable representative(s) consistent with national law is/are able to read, understand, and provide written informed consent
- •Has one (or more) identified adult caregiver who is willing to provide written informed consent for his/her own participation; is able to read, understand, and speak the designated language at the study site; either lives with the subject or sees the subject for ≥2 hours/day ≥3 days/week; agrees to accompany the subject to each study visit; and is able to verify daily compliance with study drug
- •If currently taking an acetylcholinesterase inhibitor and/or memantine at the time of Screening, the subject must have been taking such medication(s) for ≥3 months. The dosage regimen must have remained stable for ≥6 weeks and it must be planned to remain stable throughout participation in the study.
- •Able to comply with the study procedures
排除标准
- •Significant central nervous system (CNS) disorder other than Alzheimer's disease
- •Significant focal or vascular intracranial pathology seen on brain MRI scan
- •Clinical evidence or history of stroke, transient ischemic attack, significant head injury or other unexplained or recurrent loss of consciousness ≥15 minutes
- •Major depressive disorder, schizophrenia, or other psychotic disorders, bipolar disorder, substance (including alcohol) related disorders
- •Metal implants in the head (except dental), pacemaker, cochlear implants, or any other non-removable items that are contraindications to MRI
- •Resides in hospital or moderate to high dependency continuous care facility
- •History of swallowing difficulties
- •Pregnant or breastfeeding
- •Glucose-6-phosphate dehydrogenase deficiency
- •History of significant hematological abnormality or current acute or chronic clinically significant abnormality
- •Abnormal serum chemistry laboratory value at Screening deemed to be clinically relevant by the investigator
- •Clinically significant cardiovascular disease or abnormal assessments
- •Preexisting or current signs or symptoms of respiratory failure
- •Concurrent acute or chronic clinically significant immunologic, hepatic, or endocrine disease (not adequately treated) and/or other unstable or major disease other than Alzheimer's disease
- •Diagnosis of cancer within the past 2 years prior to Baseline (other than basal cell or squamous cell skin cancer or Stage 1 prostate cancer) unless treatment has resulted in complete freedom from disease for at least 2 years
- •Prior intolerance or hypersensitivity to methylthioninium-containing drug, similar organic dyes, or any of the excipients
- •Treatment currently or within 3 months before Baseline with any of the following medications (unless otherwise noted):
- •Clozapine, olanzapine (and there is no intent to initiate therapy during the course of the study)
- •Carbamazepine, primidone
- •Drugs with a warning or precaution in the labeling of methemoglobinemia at approved doses
- •Current or prior participation in a clinical trial as follows:
- •Clinical trial of a product for cognition in which the last dose was received within 90 days prior to Screening (unless confirmed to have been randomized to placebo)
- •A clinical trial of a drug, biologic, device, or medical food in which the last dose/administration was received within 28 days prior to Baseline
研究组 & 干预措施
TRx0237 200 mg/day
Experimental
干预措施: TRx0237 200 mg/day (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change from Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)
时间窗: 78 weeks
Change from Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)
时间窗: 78 weeks
Number of study participants who tolerate oral doses of TRx0237 as determined by safety parameter changes
时间窗: 78 weeks
Safety parameters include adverse events, vital signs, methemoglobin and oxygen saturation, physical and neurological examinations, laboratory tests (hematology, serum chemistry, and urinalysis), electrocardiograms, potential for serotonin toxicity, brain magnetic resonance imaging (MRI), and potential for suicide or self-harm.
次要结局
- Change from Baseline in Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)(78 weeks)
- Change from Baseline in Mini-Mental Status Examination (MMSE)(78 weeks)
- Change from Baseline in Neuropsychiatric Inventory (NPI)(78 weeks)
- Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)(78 weeks)
- Change in expected decline of whole brain volume as measured by brain MRI(78 weeks)
研究者
研究点 (95)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's DiseaseNCT01689246TauRx Therapeutics Ltd891
已完成
3 期
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)Behavioral Variant Frontotemporal Dementia (bvFTD)NCT01626378TauRx Therapeutics Ltd220
终止
2 期
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's DiseaseAlzheimer's DiseaseNCT01626391TauRx Therapeutics Ltd9
已完成
3 期
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label TreatmentAlzheimer DiseaseNCT03446001TauRx Therapeutics Ltd598
已完成
1 期
Multiple Dose Study of TRx0037Alzheimer's DiseaseNCT01253499TauRx Therapeutics Ltd31